Trial ID or NCT#

NCT02415881

Status

not recruiting iconNOT RECRUITING

Purpose

Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.

Official Title

Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

John B. Sunwoo
John B. Sunwoo
Thyroid and parathyroid surgeon, Cutaneous oncology specialist, Head and neck surgical oncologist, Head and neck surgeon, Endocrine surgeon, Surgical oncologist, Dermato-oncology specialist
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Eben Rosenthal
Eben Rosenthal
Otolaryngologist, Head and neck surgeon
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)
Vasu Divi, MD
Vasu Divi, MD
Otolaryngologist, Head and neck surgical oncologist, Surgical oncologist, Head and neck surgeon, Facial plastic surgeon
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) Masters Student in Clinical Informatics Management, admitted Summer 2021
Davud Sirjani, MD
Davud Sirjani, MD
Otolaryngologist, Head and neck surgeon, Head and neck surgical oncologist
Clinical Associate Professor, Otolaryngology (Head and Neck Surgery)
Michael J. Kaplan, MD

Contact us to find out if this trial is right for you.

CONTACT

Grace Yi
650-242-2666